

CJ-42794

Catalog No: tcsc5287



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

847728-01-2

Formula:

$C_{22}H_{17}ClFNO_4$

Pathway:

GPCR/G Protein

Target:

Prostaglandin Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 28 mg/mL (67.66 mM)

Alternative Names:

CJ-042794

Observed Molecular Weight:

413.83

Product Description

CJ-42794 is a selective prostaglandin E receptor subtype 4


(EP4) antagonist, inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5, a binding affinity that was at least 200-fold more selective for the human EP4 receptor than other human EP receptor subtypes (EP1, EP2, and EP3).

IC50 value: 8.5 (pKi) [1]

Target: EP4

in vitro: CJ-042794 competitively inhibits PGE2-evoked elevations of intracellular cAMP levels in HEK293 cells overexpressing human EP4receptor with a mean pA2 value of 8.6. PGE2 inhibits the lipopolysaccharide (LPS)-induced production of tumor necrosis factor α (TNF α) in human whole blood (HWB); CJ-042794 reverses the inhibitory effects of PGE2 on LPS-induced TNF α production in a concentration-dependent manner. [1]

in vivo: CJ-42794 significantly delays the ulcer healing in rats and mice. The expression of VEGF in primary rat gastric fibroblasts was increased by PGE2 or AE1-329 (EP4 agonist), and these responses were both attenuated by coadministration of CJ-42794.[2]



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!